Feed XENE
XE

Xenon Pharmaceuticals XENE · NASDAQ

$35.34 -3.18% (-$1.16)

Market cap
$3.53B
Enterprise value
$3.42B
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
-35.1%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.60
Free float
93.9%

About the company

Xenon Pharmaceuticals is a biotechnology company focused on developing innovative therapies for the treatment of neurological and genetic disorders. The company specializes in discovering and developing new drugs that target specific genetic pathways and ion channels critical for the proper functioning of the nervous system. Xenon focuses on rare and difficult-to-treat disorders, such as epilepsy and various neurological conditions caused by genetic mutations. The company utilizes advanced technologies to accelerate the development of these therapeutics and improve the lives of patients suffering from these diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Ian C. Mortimer

Employees

364

Headquarters

Burnaby

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy